Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.45 |
| ▸ | PRKDC | P78527 | 5/20 | 0.44 |
| ▸ | SRC | P12931 | 5/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422928 | 0.88 | SRC (0.47) | EGFRERBB2PRKDCSRC | |
| SCHEMBL248964 | 0.85 | PRKDC (0.45) | EGFRERBB2PRKDCSRCMAP2K1 | |
| SCHEMBL248798 | 0.85 | PRKDC (0.44) | EGFRERBB2PRKDCSRCMAP2K1 | |
| SCHEMBL15006907 | 0.85 | MAP2K1 (0.50) | EGFRERBB2PRKDCSRCMAP2K1 | |
| SCHEMBL15006694 | 0.84 | PRKDC (0.45) | EGFRERBB2PRKDCSRCMAP2K1 | |
| SCHEMBL247658 | 0.84 | PRKDC (0.61) | PRKDC | |
| SCHEMBL15006895 | 0.84 | PRKDC (0.43) | EGFRERBB2PRKDCSRCMAP2K1 | |
| SCHEMBL3414910 | 0.84 | PRKDC (0.43) | EGFRERBB2PRKDCSRCMAP2K1 | |
| SCHEMBL15006672 | 0.84 | PRKDC (0.43) | PRKDCMAP2K1 | |
| SCHEMBL16215861 | 0.81 | SRC (0.45) | EGFRERBB2PRKDCSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588457-B1 | PYRAZOLOQUINOLINE DERIVATIVES AS DNA-PK INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8802712-B2 | Pyrazoloquinolines | MERCK PATENT GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-8802712-B2 | Pyrazoloquinolines | MERCK PATENT GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-20130150359-A1 | PYRAZOLOQUINOLINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150359-A1 | PYRAZOLOQUINOLINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150359-A1 | PYRAZOLOQUINOLINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-13 | — | — | US | disclosed |
| EP-2588457-A1 | PYRAZOLO-QUINOLINES | Merck Patent GmbH (DE) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012000632-A1 | PYRAZOLO-QUINOLINES | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150359-A1 | PYRAZOLOQUINOLINES | PLK1, PKN3, PKN1 | EGFR 911/4885ERBB2 672/4885PRKDC 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.